Kisspeptin-10: Research, Mechanism, and Evidence for Reproductive Hormone Regulation

What it is

Kisspeptin-10 is the short active piece of kisspeptin, a signaling molecule made in the brain. Kisspeptin sits at the very top of the chain of hormones that controls testosterone, estrogen, and fertility. That chain is called the HPG axis, short for hypothalamus, pituitary, and gonads, the three organs it links.

The full molecule, kisspeptin-54, is a neuropeptide of 54 amino acids made from the KISS1 gene. Kisspeptin-10 is the last 10 of those, and that fragment is enough to fully activate the kisspeptin receptor, called KISS1R or GPR54.

Its importance became clear when researchers found that people born with a broken KISS1 or KISS1R gene never go through puberty and make no reproductive hormones (Seminara et al., 2003), (Topaloglu et al., 2012). That made kisspeptin one of the biggest findings in reproductive medicine of the past twenty years.

What it is studied for

Most of the research is about fertility: triggering egg maturation in IVF, restarting hormone pulses in women whose periods have stopped, and testing where in the hormone chain a problem lies. Some studies look at raising testosterone in men.

A constant supply of kisspeptin shuts the axis down rather than driving it, so continuous dosing is also being explored as a possible contraceptive.

What the evidence actually shows

In humans

Kisspeptin binds to receptors on nerve cells in the hypothalamus that make GnRH, the hormone that tells the pituitary gland to act. GnRH travels through the hypophyseal portal system to the pituitary, which then releases two hormones, LH and FSH. In men, LH tells the testes to make testosterone and FSH supports sperm production. In women, LH and FSH drive egg development, ovulation, and estrogen and progesterone.

Kisspeptin is the strongest known natural trigger for GnRH. In healthy men, kisspeptin infused into a vein produced clear, dose-dependent rises in LH and then testosterone, with LH peaking within about 30 minutes of a single dose (Dhillo et al., 2005).

In women, the LH response changes across the menstrual cycle and is strongest just before ovulation. That finding led to trials of kisspeptin-54 as an IVF trigger, in place of the usual hCG injection that matures eggs before retrieval. Its advantage is a lower risk of ovarian hyperstimulation syndrome, a serious complication in which the ovaries over-respond. Egg retrievals and pregnancies were successful (Jayasena et al., 2014), (Abbara et al., 2015).

In women with hypothalamic amenorrhea, where periods stop because of stress, low body weight, or heavy exercise, a kisspeptin injection restarted LH pulses. That showed the downstream machinery still works and the missing piece is the kisspeptin and GnRH signal (Jayasena et al., 2009). The same idea underlies a kisspeptin stimulation test, which helps locate where in the axis a problem sits.

Human infusion studies also show the catch. Continuous kisspeptin raises LH at first, then LH falls as the receptors stop responding, a process called desensitization or tachyphylaxis. This is the single most important limitation of the molecule.

In animals

The receptor biology and the desensitization effect were both worked out in animals first. Because human studies exist for the main claims, this page leans on those rather than the animal work.

From user reports

People who use kisspeptin-10 outside clinics report subcutaneous injections of 100 to 300 mcg, two or three times a day, for 2 to 4 weeks. They usually hope to raise testosterone or restart hormone production after a steroid cycle. We could not find a published study of either use.

How it is used in studies

Human studies gave 1.0 nmol/kg into a vein as a single dose to produce an LH spike, or 6.4 nmol/kg under the skin, roughly 5 to 8 mcg/kg. For an 80 kg person that is about 400 to 640 mcg per dose. Effects are brief, because the half-life, the time for the body to clear half a dose, is about 28 minutes.

Timing matters more than amount. One large daily dose can lower LH and testosterone instead of raising them, so research protocols use single test doses or pulses. That need for several small doses a day is the main practical barrier to using kisspeptin-10 outside a clinic.

For comparison, hCG acts further down the chain and is dosed two or three times a week. Clomiphene is a daily pill that blocks estrogen’s feedback signal and so raises LH and FSH. Both are far more convenient, which is why kisspeptin-10 has not displaced them for testosterone support. See our muscle growth guide for the wider picture.

Side effects and unknowns

In clinical studies kisspeptin-10 was well tolerated at every dose tested, in both sexes. Reported side effects were facial flushing, mild abdominal discomfort, and ordinary injection-site reactions. No serious adverse events have been reported, and blood sugar and other metabolic measures did not change at studied doses.

The main risk is getting the dosing pattern wrong. Continuous or once-daily high-dose use can suppress reproductive hormones, the opposite of what most users want.

Two things are unknown. Studies have been short, so the effect of repeated courses over months or years is unstudied. And because it raises LH and FSH, kisspeptin-10 raises estrogen alongside testosterone, since the body converts some testosterone to estrogen through an enzyme called aromatase. In men the estrogen rise is usually in proportion to the testosterone rise, but individual responses vary.

Legal status

In the United States, kisspeptin-10 is a research chemical. It is not FDA approved for any use and is under clinical investigation for IVF.

Internationally, it is being studied at academic centers, especially Imperial College London, and is not approved for clinical use anywhere outside trials. WADA does not list it by name, but it may fall under the catch-all rules for peptide hormones that affect the HPG axis.

Bottom line

Kisspeptin-10 has better human evidence than most peptides on this site, including controlled studies showing it raises LH and testosterone, and IVF trials of its longer cousin. The catch is that it only works in pulses, which means several injections a day. For that reason it remains a research and clinical tool, not a practical hormone booster.

Frequently Asked Questions

Can kisspeptin-10 replace hCG for testosterone support?

Both raise LH and testosterone. Kisspeptin-10 needs two or three doses a day; hCG needs two or three a week. Acting at the top of the chain is appealing in theory, but the dosing burden outweighs it for routine use.

Is kisspeptin-10 useful for post-cycle therapy (PCT)?

In theory it could restart the axis from the top. In practice its short half-life and pulse requirement make it less workable than established approaches such as clomiphene or tamoxifen with hCG. No PCT study using kisspeptin-10 has been published.

Does kisspeptin-10 increase estrogen?

Indirectly, yes. More LH and FSH means more testosterone, and some of that is converted to estrogen. In men the rise is usually proportional and often needs no extra management, though people differ.

Why is kisspeptin-10 used instead of the full-length kisspeptin-54?

Both activate the receptor fully. Kisspeptin-10 is smaller and easier to make. Kisspeptin-54 lasts longer in the body, which is why some IVF research used it. The choice depends on the setting.

Could kisspeptin-10 help diagnose reproductive hormone problems?

Yes. A kisspeptin stimulation test shows whether the axis can respond to an upstream signal, which helps pinpoint where a problem lies. This is one of its most established research uses.

How does kisspeptin-10 relate to muscle growth?

Higher testosterone could in theory support muscle growth. The dosing demands and simpler alternatives mean it is rarely used for that. See our muscle growth guide.

References

1. Dhillo WS, et al. “Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males.” J Clin Endocrinol Metab. 2005;90(12):6609-15. PubMed
2. Jayasena CN, et al. “Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization.” J Clin Invest. 2014;124(8):3667-77. PubMed
3. Abbara A, et al. “Efficacy of Kisspeptin-54 to Trigger Oocyte Maturation in Women at High Risk of Ovarian Hyperstimulation Syndrome.” J Clin Endocrinol Metab. 2015;100(9):3322-31. PubMed
4. Jayasena CN, et al. “Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea.” Clin Endocrinol. 2009;71(2):185-91. PubMed
5. Seminara SB, et al. “The GPR54 gene as a regulator of puberty.” N Engl J Med. 2003;349(17):1614-27. PubMed
6. Abbara A, et al. “Kisspeptin is a novel regulator of human fetal adrenocortical development and function.” J Clin Endocrinol Metab. 2018;103(9):3296-3307. [research needed, verify PMID]
7. Topaloglu AK, et al. “Inactivating KISS1 mutation and hypogonadotropic hypogonadism.” N Engl J Med. 2012;366(7):629-35. PubMed

See also

• Peptide
  CJC-1295: What the Evidence Says About This GHRH Analog

  CJC-1295 is a longer-lasting version of GHRH, the signal that tells the pituitary to release growth hormone. The DAC form raised GH and IGF-1 for days in one small trial; the no-DAC form (Mod GRF 1-29) has no human trial of its own.

• Peptide
  Ipamorelin: What the Evidence Says About This Selective GH Secretagogue

  Ipamorelin is a five-amino-acid peptide that mimics ghrelin to release a pulse of growth hormone, and unlike its predecessors does it without raising cortisol, prolactin, or hunger. Human data: one dosing study and one abandoned surgery trial.

• Peptide
  MK-677 (Ibutamoren): What the Research Shows About This Oral GH Secretagogue

  MK-677 (ibutamoren) is an oral drug, not a peptide, that mimics ghrelin to raise growth hormone and IGF-1 around the clock. It has more human trial data than most peptides here, including a two-year study, and the body-composition results were modest.